1. Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance
   Wei Sun et al, 2019, International Journal of Cancer CrossRef
2. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
   Dirk Brehmer et al, 2021, Molecular Cancer Therapeutics CrossRef
3. Targeting bromodomain and extraterminal proteins in breast cancer
   Jennifer M. Sahni et al, 2018, Pharmacological Research CrossRef
4. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
   Caroline C. Farrington et al, 2020, Journal of Biological Chemistry CrossRef
5. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers
   Caroline C. Farrington et al, 2020, Journal of Biological Chemistry CrossRef
6. Epigenetic Landscape in Leukemia and Its Impact on Antileukemia Therapeutics
   Bingzhi He et al, 2019, Germ Line Mutations Associated Leukemia CrossRef
7. Transcription Factor AP4 Mediates Cell Fate Decisions: To Divide, Age, or Die
   Matthew Man-Kin Wong et al, 2021, Cancers CrossRef
8. Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity
   Haruka Orihara et al, 2023, Biomedicine & Pharmacotherapy CrossRef
9. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling
   Huan-Tian Zhang et al, 2017, Journal of Cellular Biochemistry CrossRef
10. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination
    Xiaofang Wu et al, 2021, Journal for ImmunoTherapy of Cancer CrossRef
11. Mdivi-1: Effective but complex mitochondrial fission inhibitor
    Seor I Ahn et al, 2024, Biochemical and Biophysical Research Communications CrossRef
12. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo
    Yu Zhang et al, 2019, Clinical Cancer Research CrossRef
13. RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma
    Ann C Mladek et al, 2022, Neuro-Oncology CrossRef
14. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma
    Rebecca Kohnken et al, 2019, Journal of Investigative Dermatology CrossRef
15. A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis
    Cuiting Peng et al, 2019, Bioscience Reports CrossRef
16. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)
    Voraporn Yongprayoon et al, 2024, Oncology Reports CrossRef
17. GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors
    Vicky Yamamoto et al, 2024, Neoplasia CrossRef
18. SOX9 is controlled by the BRD4 inhibitor JQ1 via multiple regulation mechanisms
    Seong Hwi Hong et al, 2019, Biochemical and Biophysical Research Communications CrossRef
19. Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression
    Xiaoran Wang et al, 2019, Investigative Opthalmology & Visual Science CrossRef
20. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
    Yingxin Pang et al, 2022, Journal of Translational Medicine CrossRef